Abstract: Objective To observe the effect of Dengzhan Shengmai capsule combined with tirofiban on ischemic stroke, and to provide reference for the combination of traditional Chinese and Western medicine in the treatment of ischemic stroke. Methods From January, 2017 to April, 2018, 112 patients with acute ischemic stroke were randomly assigned to the control group or the observation group, with 56 cases in each group. The control group was given routine and symptomatic treatment, tirofiban intravenous infusion and Dengzhan Shengmai placebo capsule were given, too. The treatment method of the observation group changed the placebo to Dengzhan Shengmai capsule. Before and after treatment, the two groups were measured by the National Institutes of Health Stroke Scale (NIHSS), the Modified Rankin scale (MRS) and the Barthel scale (BS) to the patients. At the same time, the coagulation function indexes were detected, the possible adverse drug reactions were recorded, and the SPSS 22.0 statistical software was used for statistical analysis. Results There was no statistical difference in general clinical data between the two groups (P>0.05). After treatment,the score of NIHSS and MRS in the observation group were lower than that of the control group (P<0.05), and the score of BS was higher than that of the control group (P<0.05). After the treatment, the activated partial thromboplastin time (APTT) and the international standardized ratio (INR) in the observation group were higher than those of the control group (P<0.05). No serious adverse reactions were found in the two groups. Conclusion The combination of Dengzhan Shengmai capsule combined with tirofiban can play a good role in promoting the recovery of nerve function and improving the index of coagulation function in the patients with ischemic stroke,and the adverse drug reaction is less.